Yantai Shuangta Food (SZSE:002481) Seems To Use Debt Quite Sensibly
Yantai Shuangta Food (SZSE:002481) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know worries about.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. Importantly, Yantai Shuangta Food Co., Ltd. (SZSE:002481) does carry debt. But the more important question is: how much risk is that debt creating?
霍華德馬克斯先生說得好:與其擔心股價波動不如擔心永久性損失帶來的風險,這也是每個實際投資者都會擔心的。因此,當您考慮一隻股票的風險時,有必要考慮其負債,因爲過高的負債可能會使公司陷入困境。值得注意的是,瑞康醫藥股份有限公司(SZSE:002481)確實存在負債。但更重要的問題是:這些負債產生了多大的風險?
When Is Debt A Problem?
什麼時候負債才是一個問題?
Generally speaking, debt only becomes a real problem when a company can't easily pay it off, either by raising capital or with its own cash flow. If things get really bad, the lenders can take control of the business. However, a more common (but still painful) scenario is that it has to raise new equity capital at a low price, thus permanently diluting shareholders. Of course, the upside of debt is that it often represents cheap capital, especially when it replaces dilution in a company with the ability to reinvest at high rates of return. When we examine debt levels, we first consider both cash and debt levels, together.
一般來說,只有當一家公司無法通過籌集資本或使用自己的現金流輕鬆償還債務時,債務才會成爲真正的問題。如果情況變得非常糟糕,債權人可以接管企業。然而,一個更常見(但仍然令人痛苦的)情況是:它必須以低價募集新的股本,從而永久性稀釋股東權益。當然,債務的好處在於它通常代表着廉價資本,尤其是當它替代那些能夠以高回報率再投資的公司的稀釋時。當我們考慮債務水平時,我們首先考慮現金和債務水平的綜合影響。
How Much Debt Does Yantai Shuangta Food Carry?
瑞康醫藥承擔了多少負債?
You can click the graphic below for the historical numbers, but it shows that as of March 2024 Yantai Shuangta Food had CN¥958.4m of debt, an increase on CN¥853.1m, over one year. However, because it has a cash reserve of CN¥669.3m, its net debt is less, at about CN¥289.1m.
您可以單擊下面的圖表查看歷史數據,但它顯示,截至2024年3月,瑞康醫藥負債95840萬人民幣,較去年增加了85310萬人民幣。但是,由於其現金儲備爲66930萬人民幣,因此其淨負債少於28910萬人民幣。
How Strong Is Yantai Shuangta Food's Balance Sheet?
瑞康醫藥的資產負債表有多強?
According to the last reported balance sheet, Yantai Shuangta Food had liabilities of CN¥1.26b due within 12 months, and liabilities of CN¥218.6m due beyond 12 months. On the other hand, it had cash of CN¥669.3m and CN¥315.0m worth of receivables due within a year. So it has liabilities totalling CN¥494.3m more than its cash and near-term receivables, combined.
根據上次披露的資產負債表,瑞康醫藥有126億人民幣的負債需在12個月內償還,21860萬人民幣的負債需在12個月以上償還。另一方面,它有66930萬人民幣現金和31500萬人民幣的應收賬款需在一年內到期。因此,其負債總額比其現金和近期應收賬款的總和多了49430萬人民幣。
Of course, Yantai Shuangta Food has a market capitalization of CN¥5.16b, so these liabilities are probably manageable. However, we do think it is worth keeping an eye on its balance sheet strength, as it may change over time.
當然,瑞康醫藥的市值爲51.6億人民幣,因此這些負債可能是可以被管理的。但是,我們確實認爲值得關注其資產負債表的強度,因爲它可能會隨着時間的推移而發生變化。
We use two main ratios to inform us about debt levels relative to earnings. The first is net debt divided by earnings before interest, tax, depreciation, and amortization (EBITDA), while the second is how many times its earnings before interest and tax (EBIT) covers its interest expense (or its interest cover, for short). This way, we consider both the absolute quantum of the debt, as well as the interest rates paid on it.
Service Corporation International的債務是其EBITDA的3.5倍,而其EBIT可覆蓋其利息開支的3.7倍。綜合考慮,雖然我們不希望看到債務水平上升,但我們認爲它可以應對當前的槓桿。好消息是,Service Corporation International在過去12個月中將其EBIT提高了2.9%,從而逐漸降低了其相對於收益的債務水平。毫無疑問,我們從資產負債表中獲得了有關債務的大部分內容。但是,相對於資產負債表,更重要的是未來收益,這將決定Service Corporation International維持健康資產負債表的能力。如果您關注未來,您可以查看此免費報告,其中有分析師的利潤預測。
Yantai Shuangta Food's net debt is only 0.87 times its EBITDA. And its EBIT easily covers its interest expense, being 47.0 times the size. So you could argue it is no more threatened by its debt than an elephant is by a mouse. It was also good to see that despite losing money on the EBIT line last year, Yantai Shuangta Food turned things around in the last 12 months, delivering and EBIT of CN¥178m. The balance sheet is clearly the area to focus on when you are analysing debt. But you can't view debt in total isolation; since Yantai Shuangta Food will need earnings to service that debt. So if you're keen to discover more about its earnings, it might be worth checking out this graph of its long term earnings trend.
瑞康醫藥的淨負債只有其EBITDA的0.87倍。而其EBIT輕鬆覆蓋了利息支出,規模爲其47倍。因此,您可以認爲其受到負債的威脅不比大象受到老鼠的威脅更多。去年,雖然瑞康醫藥在EBIT線上虧損了,但在過去12個月中,成功扭虧爲盈並實現了1.78億元人民幣的EBIT。當您分析債務時,資產負債表顯然是要重點關注的區域。但是,您不能將債務完全孤立地看待,因爲瑞康醫藥需要收益來償還債務。因此,如果您想了解更多有關其收益的信息,可以查看其長期收益趨勢圖表。
Finally, a business needs free cash flow to pay off debt; accounting profits just don't cut it. So it's worth checking how much of the earnings before interest and tax (EBIT) is backed by free cash flow. Over the most recent year, Yantai Shuangta Food recorded free cash flow worth 66% of its EBIT, which is around normal, given free cash flow excludes interest and tax. This cold hard cash means it can reduce its debt when it wants to.
最後,一家企業需要自由現金流來償還債務;會計利潤並不足以擺脫負債。因此,核實多少利息和稅費備付資金(Ebit)由自由現金流支持是值得的。在最近的一年中,瑞康醫藥記錄的自由現金流價值相當於其EBIT的66%,這是比較正常的,因爲自由現金流不包括利息和稅收。這筆實打實的現金意味着它可以在需要時減少其債務。
Our View
我們的觀點
The good news is that Yantai Shuangta Food's demonstrated ability to cover its interest expense with its EBIT delights us like a fluffy puppy does a toddler. And the good news does not stop there, as its conversion of EBIT to free cash flow also supports that impression! When we consider the range of factors above, it looks like Yantai Shuangta Food is pretty sensible with its use of debt. While that brings some risk, it can also enhance returns for shareholders. There's no doubt that we learn most about debt from the balance sheet. However, not all investment risk resides within the balance sheet - far from it. For example, we've discovered 2 warning signs for Yantai Shuangta Food (1 makes us a bit uncomfortable!) that you should be aware of before investing here.
好消息是,瑞康醫藥用其EBIT輕鬆覆蓋了其利息支出,這讓我們像毛絨絨的小狗一樣喜極而泣。好消息並不止於此,它的EBIT轉爲自由現金流的能力也支持了這一印象!當我們考慮上述因素的範圍時,看起來瑞康醫藥在利用債務方面相當明智。雖然這帶來了一些風險,但也可能增加股東的回報。毫無疑問,我們從資產負債表中獲得了很多關於債務的信息。但是,並非所有投資風險都存在於資產負債表中。例如,我們發現了2項瑞康醫藥的警示信號(1項讓我們有點不舒服!),在在投資此處前,您應該知曉這些警示信號。
Of course, if you're the type of investor who prefers buying stocks without the burden of debt, then don't hesitate to discover our exclusive list of net cash growth stocks, today.
當然,如果您是那種喜歡購買沒有債務負擔的股票的投資者,那麼不要猶豫,立即發現我們獨家的淨現金增長股票列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。